Propanc Biopharma Inc (PPCBD) Q3 2024 Earnings Report

Propanc Biopharma Inc (PPCBD) reported calendar QQ3 2024 results (quarter ended 2024-03-31) with a continued preclinical focus and no disclosed revenue. Key figures show a net loss of $526,700 and an EBITDA loss of $389,061, driven by operating expenses of $420,867 and SG&A/R&D spending of $420k and $65k respectively. Operating cash flow was negative at $102,810, and cash at period-end was just $6,222, underscoring a fragile liquidity position. The balance sheet shows total assets of $37,337 against total liabilities of $3,736,854 and negative stockholders’ equity of $-3,699,517, indicating a leveraged capital structure and meaningful solvency risk. The company’s business remains in early-stage development, with lead program PRP in preclinical phases and active collaborations with the University of Jaén and the University of Granada; no explicit revenue guidance or forward-looking targets are presented in the disclosed filing.